prednisolone reference
Reference image
(prednisolone · DailyMed)
Registered Kenya · PPB

OLSOLONE SYRUP

EACH 5ML CONTAINS PREDNISOLONE SODIUM PHOSPHATE 6.7MG (EQUIVALENT TO 5MG PREDNISOLONE BASE).

11868 5MG GENERIC/BIOSIMILARS INN generic

What it does

This medicine contains a variety of active ingredients that work together to help treat certain health conditions.

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
11868
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
EACH 5ML CONTAINS PREDNISOLONE SODIUM PHOSPHATE 6.7MG (EQUIVALENT TO 5MG PREDNISOLONE BASE).
Dosage form
5MG
Strength
-
Pack size
50ML
Therapeutic class
GENERIC/BIOSIMILARS
Manufacturer / MAH
Biopharma
Applicant / LTR
BIOPHARMA LIMITED.
Country of origin
LOCAL
Manufacturer location
Building No. 01, Road 01 Dhaka Housing Main Rd, Dhaka 1207, Bangladesh

Source: Pharmacy and Poisons Board · fetched 2026-01-28 22:04:30 · updated 2026-03-23 04:49:39

Drug Interactions

41
Check interactions

Pharmacodynamic Warnings

Prednisolone appears in TABLE 17: Drugs that reduce serum potassium

Severe (1)

Mifamurtide - decreases efficacy

Corticosteroidsarepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical

Severe Theoretical

Moderate (20)

Corticosteroids - increases exposure

Dronedarone is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.

Moderate Study

Corticosteroids - increases concentration

Miconazole is predicted to increase the concentration of corticosteroids (methylprednisolone). Monitor and adjust dose.

Moderate Theoretical

Corticosteroids - increases exposure

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.

Moderate Study

Corticosteroids - decreases exposure

Cenobamate is predicted to decrease the exposure to corticosteroids (fluticasone). Adjust dose.

Moderate Theoretical

Corticosteroids - decreases efficacy

Mifepristone is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose.

Moderate Theoretical

Unknown (20)

Aspirin - decreases concentration

Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids.

Unknown Study

Choline Salicylate - decreases concentration

Corticosteroids are predicted to decrease the concentration of cholinesalicylate. Ciclesonide → see corticosteroids Ciclosporin → see TABLE 2 p. 1517 (nephrotoxicity), TABLE 16 p. 1521 (increased seru

Unknown Study

Corticosteroids - increases exposure

Cobicistat is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).

Unknown Theoretical

Corticosteroids - increases risk of gastrointestinal perforation

Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with corticosteroids.

Unknown Theoretical

Corticosteroids - increases exposure

Idelalisib is predicted to increase the exposure to corticosteroids (betamethasone, budesonide, ciclesonide, deflazacort, dexamethasone, fludrocortisone, fluticasone, hydrocortisone, methylprednisolon

Unknown Study

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About contains

This medicine contains a variety of active ingredients that work together to help treat certain health conditions.

How it works

The active ingredients in this medicine perform specific functions to help your body in various ways, depending on the condition being treated.

Who it's for

This medicine is meant for individuals with specific health issues as determined by a healthcare provider.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About prednisolone

Prednisolone is a corticosteroid medication used to reduce inflammation and suppress the immune system.

What it treats

  • inflammation
  • allergic reactions
  • asthma
  • autoimmune diseases
  • certain types of cancer

How it works

It works by mimicking the effects of hormones your body makes in the adrenal glands, helping to reduce swelling and control the immune response.

Who it's for

Prednisolone is prescribed for people with conditions that involve inflammation or an overactive immune system.

Drug class

Corticosteroids

Cautions

  • • Be cautious if taking medications that lower potassium levels.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: contains

Contains is a term generally used to refer to formulations that include one or more active pharmaceutical ingredients. The specific effects, uses, and formulations depend on the particular drug in question. It is often used in the context of drug labels to inform about the components of a medication.

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: Prednisolone

BNF-referenced

Prednisolone is a synthetic corticosteroid that exhibits anti-inflammatory and immunosuppressive properties. It is commonly used to treat a variety of corticosteroid-responsive conditions, including inflammatory disorders, autoimmune diseases, and certain malignancies. Prednisolone works by modulating gene expression through binding to the glucocorticoid receptor, leading to decreased inflammation and altered immune responses.

Indications

  • Corticosteroid-responsive conditions
  • Autoimmune diseases
  • Inflammatory eye conditions
  • Certain malignancies
  • Chronic inflammatory disorders

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing recommendations based on age and weight.

Adults: Refer to the BNF for specific adult dosing guidelines based on the condition being treated. Doses may vary depending on the severity of the condition and the clinical response.

Mechanism of action

Prednisolone binds to the glucocorticoid receptor, resulting in altered gene expression that decreases vasodilation, capillary permeability, and leukocyte migration to sites of inflammation. It inhibits phospholipase A2, reducing the production of arachidonic acid derivatives, and suppresses pro-inflammatory transcription factors such as NF-Kappa B. This results in an anti-inflammatory effect at lower doses and immunosuppressive effects at higher doses.

Pharmacodynamics

Corticosteroids like prednisolone exert their effects by inhibiting pro-inflammatory signals and promoting anti-inflammatory signals through their action on the glucocorticoid receptor. Prednisolone has a relatively short half-life of 2.1 to 3.5 hours, and while it has a wide therapeutic window, long-term use can lead to hypothalamic-pituitary-adrenal axis suppression and increased infection risk.

Pharmacokinetics

Prednisolone is rapidly absorbed and has a short duration of action. Its pharmacokinetics involve extensive metabolism in the liver, primarily through hepatic enzymes, leading to various metabolites. The elimination half-life is approximately 2.1 to 3.5 hours, and it is primarily excreted in the urine. Chronic use can affect circadian rhythms and homeostasis.

Contra-indications

  • Known allergy to prednisolone or any of its components
  • Systemic fungal infections
  • Active tuberculosis
  • Untreated bacterial infections

Adverse effects

  • Increased susceptibility to infections
  • Gastrointestinal disturbances
  • Fluid retention
  • Hypertension
  • Cushing's syndrome
  • Osteoporosis
  • Mood changes
  • Hyperglycemia

Interactions

  • Mitotane (Moderate - decreases exposure)
  • Rifampicin (Moderate - decreases exposure)
  • Cobicistat (Unknown - increases exposure)
  • Idelalisib (Unknown - increases exposure)
  • Clarithromycin (Unknown - increases exposure)

Precautions

  • Monitor for signs of infection during therapy
  • Use with caution in patients with a history of gastrointestinal ulcers
  • Tapering of dosage may be necessary to avoid withdrawal symptoms
  • Consider potential effects on growth in pediatric patients

Pregnancy

Prednisolone is classified as a Category C drug. It should only be used if the potential benefits justify the potential risk to the fetus.

Breast-feeding

Prednisolone is excreted in breast milk. Caution should be exercised when administered to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

  • Tablets: 2 mg, 4 mg, 16 mg, 100 mg
  • Suspension for injection
  • Powder and solvent for solution for injection
BNF 85 (British National Formulary) p.776 BNF 85 (British National Formulary) p.1297 BNF 85 (British National Formulary) p.1334 BNF for Children 2019-2020 p.480 BNF for Children 2019-2020 p.715 BNF for Children 2019-2020 p.737 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Prednisolone

PubChem CID 5755

Molecular formula: C21H28O5

Mechanism of action

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels. Although altered homeostatic regulation, including disturbance of 24-h rhythms, is often observed in the patients undergoing glucocorticoid therapy, the mechanisms underlying the disturbance remains poorly understood. We report here that chronic treatment with a synthetic glucocorticoid, prednisolone, can cause alteration of circadian clock function at molecular level. Treatment of cultured hepatic cells (HepG2) with prednisolone induced expression of Period1 (Per1), and the prednisolone treatment also attenuated the serum-induced oscillations in the expression of Period2 (Per2), Rev-erbalpha, and Bmal1 mRNA in HepG2 cells. Because the attenuation of clock gene oscillations was blocked by pretreating the cells with a Per1 antisense phosphothioate oligodeoxynucleotide, the extensive expression of Per1 induced by prednisolone may have resulted in the reduced amplitude of other clock gene oscillations. Continuous administration of prednisolone into mice constitutively increased the Per1 mRNA levels in liver and skeletal muscle, which seems to attenuate the oscillation in the expressions of Per2, Rev-erbalpha, and Bmal1. However, a single daily administration of prednisolone at the time of day corresponding to acrophase of endogenous glucocorticoid levels had little effect on the rhythmic expression of clock genes. These results suggest a possible pharmacological action by prednisolone on the core circadian oscillation mechanism and indicate the possibility that the alteration of clock function induced by prednisolone can be avoided by optimizing the dosing schedule. Glucocorticoids are capable of suppressing the inflammatory process through numerous pathways. They interact with specific intracellular receptor proteins in target tissues to alter the expression of corticosteroid-responsive genes. Glucocorticoid-specific receptors in the cell cytoplasm bind with steroid ligands to form hormone-receptor complexes that eventually translocate to the cell nucleus. There these complexes bind to specific DNA sequences and alter their expression. The complexes may induce the transcription of mRNA leading to synthesis of new proteins. Such proteins include lipocortin, a protein known to inhibit PLA2a and thereby block the synthesis of prostaglandins, leukotrienes, and PAF. Glucocorticoids also inhibit the production of other mediators including AA metabolites such as COX, cytokines, the interleukins, adhesion molecules, and enzymes such as collagenase. /Glucocorticoids/

Pharmacodynamics

Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisolone has a short duration of action as the half life is 2.1-3.5 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.